RADIOPHARM THERANOSTICS LIMITED (RAD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RAD - RADIOPHARM THERANOSTICS LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.024

01 Nov
2024

0.000

OPEN

$0.03

0.000

HIGH

$0.03

1,363,482

LOW

$0.02

TARGET
$0.07 191.7% upside
FNARENA'S MARKET CONSENSUS FORECASTS
RAD: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 12.4 - 2.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 202220232024
EPS Basic xxxxxx-12.4
DPS All xxxxxx0.0
Sales/Revenue xxxxxx0.3 M
Book Value Per Share xxxxxx6.1
Net Operating Cash Flow xxxxxx-23.0 M
Net Profit Margin xxxxxx-16,024.28 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202220232024
Return on Capital Employed xxxxxx-132.26 %
Return on Invested Capital xxxxxx-132.26 %
Return on Assets xxxxxx-65.24 %
Return on Equity xxxxxx-132.26 %
Return on Total Capital xxxxxx-105.48 %
Free Cash Flow ex dividends xxxxxx-23.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202220232024
Short-Term Debt xxxxxx0 M
Long Term Debt xxxxxx0 M
Total Debt xxxxxx0 M
Goodwill - Gross xxxxxx-
Cash & Equivalents - Generic xxxxxx19 M
Price To Book Value xxxxxx0.62

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202220232024
Capex xxxxxx0.0 M
Capex % of Sales xxxxxx0.00 %
Cost of Goods Sold xxxxxx-
Selling, General & Admin. Exp & Other xxxxxx36 M
Research & Development xxxxxx20 M
Investments - Total xxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/09/2024

1

Speculative Buy

$0.07

191.67%

Radiopharm Theranostics is now funded to execute on its clinical pipeline for the next 18-24 months following a $70m institutional placement and the target is reduced to $0.07 from $0.25.

At the end of that period Bell Potter expects the two imaging assets would have generated sufficient data to support a partnering transaction or asset sale.

Lantheus, which now owns 7% of the stock, is one of the largest providers of radiopharmaceuticals in the US. The assets with potentially higher value are therapeutics for lung, brain and pancreatic cancer albeit these are yet to generate data in humans. Speculative Buy rating.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.50 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

RAD STOCK CHART

FNArena News on RAD

1
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
2
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps
3
Dr Boreham’s Crucible: Radiopharm Theronostics

Apr 13 2023 - Small Caps
4
Australian Broker Call *Extra* Edition – Mar 21, 2023

Mar 21 2023 - Daily Market Reports
5
Dr Boreham’s Crucible: Telix Pharmaceuticals

Aug 22 2022 - Small Caps